By Fineline Cube 
China-based 3SBio Inc. (HKG: 1530) has announced the receipt of Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA) for its 707, a PD-1 and VEGF bispecific antibody (BsAb). The designation is for the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
707: Development and Clinical Progress
707, developed through 3SBio’s independently established dual antibody platform, is being evaluated in Phase II studies for first-line NSCLC and metastatic colorectal cancer (mCRC), as well as advanced gynecological tumors, including endometrial and ovarian cancers, in China. The drug has also been cleared for Phase III study in first-line PD-L1 positive locally advanced or metastatic NSCLC and has obtained clinical approval in the US.-Fineline Info & Tech